Capecitabine-Associated Hematuria and Melena
Capecitabine can cause bleeding manifestations that include blood in the urine and black or tarry stools consistent with melena. [1][2][3]
Evidence for Hematuria
Blood in the urine is listed as a warning/serious adverse effect of capecitabine. [1][2][3] Severe hemorrhagic cystitis with gross hematuria has been reported in association with capecitabine-containing regimens. [4]
Evidence for Melena / Gastrointestinal Bleeding
Black or tarry stools are listed as a warning/possible sign of bleeding with capecitabine. [3] Melena is a clinical sign of gastrointestinal bleeding, typically from the upper gastrointestinal tract. [5] Severe GI bleeding temporally associated with capecitabine has been reported in case reports, including lower GI bleeding presentations. [6]
Clinical Interpretation of Symptoms
Hematuria and melena while receiving capecitabine warrant evaluation for clinically significant bleeding sources rather than attribution to benign effects. [2][5] Potential contributory mechanisms include mucosal toxicity and treatment-related effects that can predispose to bleeding. [3]
When Urgent Evaluation Is Indicated
Emergency evaluation is recommended when melena is accompanied by hemodynamic instability, syncope, severe weakness, or significant drop in hemoglobin. [5] Emergency evaluation is recommended when gross hematuria is present with clot retention, severe flank pain, or inability to maintain urine output. [4]
Immediate Management Steps
Capecitabine should be withheld and oncology/clinical care contacted promptly when serious bleeding signs such as blood in urine or black/tarry stools occur. [3][2] Concomitant anticoagulant use and other medications that increase bleeding risk should be reviewed because capecitabine has bleeding-related warnings, particularly in combination with certain blood thinners. [2]
Safety Monitoring and Reporting
Patients receiving capecitabine should be monitored for bleeding symptoms because serious bleeding can occur. [1][2][3] Suspected adverse reactions should be reported through appropriate pharmacovigilance pathways as advised in patient information. [2]